Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Temuterkib by Eli Lilly and Co for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Temuterkib is under clinical development by Eli Lilly and Co and currently in Phase I for Relapsed Acute Myeloid Leukemia....
Data Insights
Temuterkib by Eli Lilly and Co for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Temuterkib is under clinical development by Eli Lilly and Co and currently in Phase I for Refractory Acute Myeloid Leukemia....